Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13064MR)

This product GTTS-WQ13064MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13064MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7790MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ10042MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA L19-131 I
GTTS-WQ11972MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MM-005
GTTS-WQ11680MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ8567MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ15593MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VAL-1221
GTTS-WQ8139MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HH1
GTTS-WQ15923MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW